Abstract:Atrial fibrillation (AF) is a globally prevalent cardiac arrhythmia with significant genetic underpinnings, as highlighted by recent large-scale genetic studies. A prominent clinical and genetic overlap exists between AF, heritable ventricular cardiomyopathies, and arrhythmia syndromes, underlining the potential of AF as an early indicator of severe ventricular disease in younger individuals. Indeed, several recent studies have demonstrated meaningful yields of rare pathogenic variants among early-onset AF patients (∼4%–11%), most notably for cardiomyopathy genes in which rare variants are considered clinically actionable. Genetic testing thus presents a promising opportunity to identify monogenetic defects linked to AF and inherited cardiac conditions, such as cardiomyopathy, and may contribute to prognosis and management in early-onset AF patients. A first step towards recognizing this monogenic contribution was taken with the Class IIb recommendation for genetic testing in AF patients aged 45 years or younger by the 2023 American College of Cardiology/American Heart Association guidelines for AF. By identifying pathogenic genetic variants known to underlie inherited cardiomyopathies and arrhythmia syndromes, a personalized care pathway can be developed, encompassing more tailored screening, cascade testing, and potentially genotype-informed prognosis and preventive measures. However, this can only be ensured by frameworks that are developed and supported by all stakeholders. Ambiguity in test results such as variants of uncertain significance remain a major challenge and as many as ∼60% of people with early-onset AF might carry such variants. Patient education (including pretest counselling), training of genetic teams, selection of high-confidence genes, and careful reporting are strategies to mitigate this. Further challenges to implementation include financial barriers, insurability issues, workforce limitations, and the need for standardized definitions in a fast-moving field. Moreover, the prevailing genetic evidence largely rests on European descent populations, underscoring the need for diverse research cohorts and international collaboration. Embracing these challenges and the potential of genetic testing may improve AF care. However, further research—mechanistic, translational, and clinical—is urgently needed. In people with early-onset atrial fibrillation (AF), an enrichment in pathogenic or likely pathogenic variants in cardiomyopathy and or/arrhythmia syndrome-associated genes is observed (see Figure 2 for more details). The diagnostic yield of capturing people with variants in these genes is higher with younger age, family history, structural or electrocardiogram (ECG) abnormalities (see Figure 1 for more details). Uncovering these high-risk individuals for heart failure enables personalized management that will need to comprehensively assess potential risks and benefits of genetic testing results. Some benefits include genotype-informed clinical assessment such as reinterpretation of borderline left ventricular hypertrophy in the setting of hypertrophic cardiomyopathy variants as well as genetic counselling and cascade testing of family members. Potential risks include the high likelihood of variants of uncertain significance that may lead to anxiety without informing healthcare decisions. Resource constraints in clinical settings might lead to further inequity for people without access to academic centres with the necessary infrastructure to offer such genetic testing services or genetic counselling (see Figure 3 for more details).

Non-atrial fibrillation cardiac phenotypes associated with common atrial fibrillation genotypic risk

Identification of a KCNE2 Gain-of-Function Mutation in Patients with Familial Atrial Fibrillation

KCNQ1 Gain-of-function Mutation in Familial Atrial Fibrillation

Epistatic Effects of Potassium Channel Variation on Cardiac Repolarization and Atrial Fibrillation Risk

Genetic testing in early-onset atrial fibrillation

Discrete mechanistic pathways underlying genetic predisposition to atrial fibrillation are associated with different intermediate cardiac phenotypes and risk of cardioembolic stroke

Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes

Letter to the EditorPrevalence and spectrum of GATA6 mutations associated with familial atrial fibrillation

Atrial fibrillation variant-to-gene prioritization through cross-ancestry eQTL and single-nucleus multiomic analyses

Genetics and Pharmacogenetics of Atrial Fibrillation: A Mechanistic Perspective

Genetic aspects associated with increased risk of developing atrial fibrillation

Genetic Polymorphism of KCNH2 Confers Predisposition of Acquired Atrial Fibrillation in Chinese

Common variants for atrial fibrillation: results from genome-wide association studies

Large-scale Analyses of Common and Rare Variants Identify 12 New Loci Associated with Atrial Fibrillation

A Network and Pathway Analysis of Genes Associated With Atrial Fibrillation

A KCNQ1 Mutation Causes a High Penetrance for Familial Atrial Fibrillation

Abstract 10816: Causal Effect of Atrial Fibrillation on Cardiovascular Diseases - A Mendelian Randomization Analysis in the Million Veteran Program

Pathophysiology, molecular mechanisms, and genetics of atrial fibrillation

Clinical and Genetic Atrial Fibrillation Risk and Discrimination of Cardioembolic From Noncardioembolic Stroke

Genetic Susceptibility to Arrhythmia Phenotypes in a Middle Eastern Cohort of 14,259 Whole-Genome Sequenced Individuals

Identification of potential crucial genes in atrial fibrillation: a bioinformatic analysis